10-K: MDB Capital Holdings Reports FY2024 Results, Navigates Deconsolidation and Strategic Shifts

MDB Capital Holdings reports its FY2024 financial results, highlighting the deconsolidation of eXoZymes, strategic shifts in operations, and ongoing efforts to strengthen internal controls.

Summary

• MDB Capital Holdings, a foundational platform specializing in financing startups, reported its FY2024 results.
• The company's strategy involves acting as founders, providing initial capital, and assisting with structuring plans for partner companies.
• A key event in 2024 was the deconsolidation of eXoZymes following its IPO, which reduced MDB's ownership to 47% and resulted in a gain of $39,307,217.
• The company operates through two reportable segments: broker-dealer & intellectual property service and technology development.
• MDB is addressing a material weakness in internal control over financial reporting related to the proper identification and accounting treatment of the deconsolidation of eXoZymes.
• The company is implementing formalized policies and procedures, establishing a review framework, and consulting with external accounting experts to remediate this weakness.
• Public Ventures, a subsidiary, began self-clearing operations of U.S. equity securities in January 2024.
• MDB Minnesota One (M1) entered into a Patent and Know-How License Agreement with the Mayo Foundation for Medical Education and Research to develop a small molecule anti-senescence platform.
• The company is managing its operations to avoid regulation under the Investment Company Act of 1940.
• The company is subject to risks associated with the political, economic, and regulatory environments in both the United States and Nicaragua.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company reports a net income and a significant gain on the deconsolidation of eXoZymes, it also faces challenges such as a decrease in fee income, an increase in compensation expense, and a material weakness in internal control over financial reporting. The company's future outlook is positive, but there are also risks associated with its operations and the external environment.

Positives

• The company reported a net income attributable to MDB Capital Holdings, LLC of $11,692,091 for FY2024, compared to a net loss of $6,968,817 in FY2023.
• The company recognized a gain of $39,307,217 on the deconsolidation of eXoZymes following its IPO.
• Public Ventures began self-clearing operations of U.S. equity securities in January 2024.
• MDB Minnesota One (M1) entered into a Patent and Know-How License Agreement with the Mayo Foundation for Medical Education and Research to develop a small molecule anti-senescence platform.

Negatives

• The company is addressing a material weakness in internal control over financial reporting related to the proper identification and accounting treatment of the deconsolidation of eXoZymes.
• Fee income from the broker-dealer segment decreased from $4,233,120 in 2023 to $2,220,620 in 2024.
• Compensation expense increased significantly from $8,627,022 in 2023 to $20,056,796 in 2024, primarily due to the recognition of restricted stock units.

Risks

• The company is addressing a material weakness in internal control over financial reporting related to the proper identification and accounting treatment of the deconsolidation of eXoZymes.
• The company is subject to risks associated with the political, economic, and regulatory environments in both the United States and Nicaragua.
• The company is managing its operations to avoid regulation under the Investment Company Act of 1940, which may require it to buy, sell, or retain assets when it would otherwise not wish to do so.
• The company's success depends on its ability to make good decisions regarding the deployment of capital into new or existing partner companies and, ultimately, the performance of its partner companies, both of which are uncertain.
• The company may require additional capital to support operations and business growth and to fund its partner companies; this capital might not be available when needed.

Future Outlook

The company plans to continue its strategy of identifying and developing partner companies, focusing on early-stage technologies with high growth potential. MDB will also focus on strengthening its internal controls and managing its operations to avoid regulation under the Investment Company Act of 1940.

Management Comments

• Management is committed to strengthening its internal control over financial reporting and addressing the material weakness related to the identification and treatment of complex accounting matters.
• Management believes that the corrective actions will strengthen the overall financial governance, positioning the company for sustainable growth and success.

Industry Context

MDB Capital Holdings operates in the competitive venture capital and investment banking industries, facing competition from traditional venture capital firms, other funds specializing in microcap and small cap investing, and investment banks focusing on microcap and small cap companies. The company's strategy of focusing on early-stage technologies and building a community of long-term investors differentiates it from some of its competitors.

Comparison to Industry Standards

• MDB Capital Holdings' business model of public venture capital is unique compared to traditional venture capital firms like Sequoia Capital or Andreessen Horowitz, which typically invest in private companies.
• The company's focus on microcap and small cap companies is similar to investment banks like Roth Capital Partners or Maxim Group, but MDB Capital Holdings also provides intellectual property validation services through PatentVest.
• The company's strategy of building a community of long-term investors is similar to crowdfunding platforms like Kickstarter or Indiegogo, but MDB Capital Holdings focuses on more sophisticated investors and provides more comprehensive support to its partner companies.
• The company's investment in MDB Minnesota One to develop a small molecule anti-senescence platform is similar to other biotechnology companies like Calico or Altos Labs, which are also focused on longevity and age-related diseases.

Management Changes

Corporate Governance

Legal Proceedings

• The company may from time to time become a party to various legal proceedings arising in the ordinary course of its business.

Related Party Transactions

• Marlett and DiGiandomenico own MDB Capital S.A., a Nicaraguan entity, that provides services to the Company and its subsidiaries on an out-source, as requested basis.
• PatentVest, a 100% entity owned by MDB Capital Holdings, LLC, engaged in transactions with ENDRA Life Sciences Inc, a company for which one of our executive officer serve as a board member, Anthony DiGiandomenico, our Chief of Transactions.
• PatentVest, a 100% entity owned by MDB Capital Holdings, LLC, engaged in transactions with eXoZymes, a company of which the company owns 47% of.

Stakeholder Impact

• Shareholders may experience volatility in the price of the company's Class A Common Shares.
• Shareholders may be subject to restrictions on deductibility of expenses and other losses.
• The company's ability to retain its senior professionals and recruit additional professionals is critical to the success of its business.
• The company's operations are subject to risks associated with the political, economic, and regulatory environments in both the United States and Nicaragua.

Next Steps

• The company is implementing formalized policies and procedures, establishing a review framework, and consulting with external accounting experts to remediate the material weakness in internal control over financial reporting.
• The company will continue to monitor the political and economic environment in Nicaragua and adjust its business plan accordingly.
• The company will continue to develop its science technologies and the products that it can offer to commercialization entities.

Key Dates

Keywords

MDB Capital Holdings, eXoZymes, Public Ventures, PatentVest, MDB Minnesota One, financial results, deconsolidation, internal control, broker-dealer, intellectual property, technology development, IPO, investment banking, senescence platform